Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

Barbara S Wiggins; Joseph J Saseen; Robert L Page 2nd; Brent N Reed; Kevin Sneed; John B Kostis; David Lanfear; Salim Virani; Pamela B Morris; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; Council on Quality of Care and Outcomes Research; and Council on Functional Genomics and Translational Biology

doi:10.1161/CIR.0000000000000456

Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

Circulation. 2016 Nov 22;134(21):e468-e495. doi: 10.1161/CIR.0000000000000456. Epub 2016 Oct 17.

Authors

Barbara S Wiggins, Joseph J Saseen, Robert L Page 2nd, Brent N Reed, Kevin Sneed, John B Kostis, David Lanfear, Salim Virani, Pamela B Morris; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; Council on Quality of Care and Outcomes Research; and Council on Functional Genomics and Translational Biology

PMID: 27754879
DOI: 10.1161/CIR.0000000000000456

No abstract available

Keywords: AHA Scientific Statements; anti-arrhythmic agents; anticoagulants; calcium channel blockers; cardiovascular disease; drug-related side effects and adverse reactions; fenofibrate/fenofibric acid derivatives; gemfibrozil; hydroxymethylglutaryl-CoA reductase inhibitors; immunosuppressive agents.

Publication types

Practice Guideline
Review

MeSH terms

American Heart Association*
Cardiovascular Diseases / diagnosis
Cardiovascular Diseases / drug therapy*
Cardiovascular Diseases / epidemiology
Clinical Decision-Making
Comorbidity
Consensus
Drug Interactions
Dyslipidemias / diagnosis
Dyslipidemias / drug therapy*
Dyslipidemias / epidemiology
Evidence-Based Medicine
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics
Polypharmacy
Risk Assessment
Risk Factors
Treatment Outcome
United States

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors